Skip to main content
SpringerLink
Log in

Regulation of interleukin-6 secretion from breast cancer cells and its clinical implications

  • Review Article
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

Interleukin (IL)-6 may play possible roles in the proliferation and metastasis of cancer cells, in the development of osteolysis and humoral hypercalcemia, and in the regulation of estrogen production in breast cancer tissues. IL-6 is also suggested to be a cachectic factor in cancer patients. A decrease in serum IL-6 levels induced by medroxyprogesterone acetate (MPA) has been reported to correlate with a reversion of body weight loss in patients with advanced breast cancer. To elucidate the mechanisms of action of the anti-cachectic effect of MPA its effects on IL-6 secretion from the KPL-4 cell line, the first human breast cancer cell line to secrete IL-6 and to induce cachexia, were explored. It has been suggested that an inhibitory effect of MPA on IL-6 secretion from breast cancer cells causes the anti-cachectic effect of MPA. Our other studies have revealed that 5′-fluorouridine (5′-DFUR) inhibits the growth of KPL-4 tumors and decreases IL-6 levels in both serum and tumor tissues. Decreasing serum IL-6 levels resulted in alleviation of body weight loss. Docetaxel increased IL-6 levels in both serum and KPL-4 tumors, but combined treatment with docetaxel and 5′-DFUR resulted not only in a potent antitumor effect but also in a drastic decrease of serum IL-6 levels. In the present paper the possible roles of IL-6 in the development and progression of breast cancer are reviewed, and the regulatory mechanisms of IL-6 secretion from breast cancer cells and the possible clinical implications of decreasing IL-6 secretion by therapeutic agents are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

IL:

Interleukin

MPA:

Medroxyprogesterone acetate

TNF:

Tumor necrosis factor

HHM:

Humoral hypercalcemia of malignancy

5′-DFUR:

5′-fluorouridine

PD-ECGF:

Platelet-derived endothelial cell growth factor

References

  1. Kishimoto T: The biology of interleukin 6.Blood 74:1–10, 1989.

    PubMed  CAS  Google Scholar 

  2. Chiu JJ, Sgagias MK, Cowan KH: Interleukin 6 acts as a paracrine growth factor in human mammary carcinoma cell lines.Clin Cancer Res 2:215–221, 1996.

    PubMed  CAS  Google Scholar 

  3. Asgeirsson KS, Olafsdottir K, Jonasson JG,et al: The effects of IL-6 on cell adhesion and e-cadherin expression in breast cancer.Cytokine 10:720–728, 1998.

    Article  PubMed  CAS  Google Scholar 

  4. Di Carlo E, Modesti A, Castrilli G,et al: Interleukin 6 gene-transfected mouse mammary adenocarcinoma: tumour cell growth and metastatic potential.J Pathol 182:76–85, 1997.

    Article  PubMed  CAS  Google Scholar 

  5. Speirs V, Walton DS, Hall MC,et al: In vivo andin vitro expression of steroid-converting enzymes in human breast tumours; Associations with interleukin- 6.Br J Cancer 81:690–695, 1999.

    Article  PubMed  CAS  Google Scholar 

  6. Miller WR, Mullen P, Sourdaine P,et al: Regulation of aromatase activity within the breast.J Steroid Biochem Mol Biol 61:193–202, 1997.

    PubMed  Google Scholar 

  7. Purohit A, Wang DY, Ghilchik MW,et al: Regulation of aromatase and sulphatase in breast tumour cells.J Endocrinol 150 (Suppl):S65–71, 1996.

    PubMed  CAS  Google Scholar 

  8. Greenfield EM, Bi Y, Miyauchi A: Regulation of osteoclast activity.Life Sci 65:1087–1102, 1999.

    Article  PubMed  CAS  Google Scholar 

  9. Nagai Y, Yamato H, Akaogi K,et al: Role of inter-leukin-6 in uncoupling of bon.in vivo in a human squamous carcinoma coproducing parathyroid hormone-related peptide and interleukin-6.J Bone Miner Res 13:664–672, 1998.

    Article  PubMed  CAS  Google Scholar 

  10. Weissglas MG, Schamhart DH, Lowik CW,et al: The role of interleukin-6 in the induction of hypercalcemia in renal cell carcinoma transplanted into nude mice.Endocrinol 138:1879–1885, 1997.

    Article  CAS  Google Scholar 

  11. Strassmann G, Fong M, Kenney JS,et al: Evidence for the involvement of interleukin 6 in experimental cancer cachexia.J Clin Invest 89:1681–1684, 1992.

    Article  PubMed  CAS  Google Scholar 

  12. Ohe Y, Podack ER, Olsen KJ,et al: Interleukin-6 cDNA transfected Lewis lung carcinoma cells show unaltered net tumor growth rate but cause weight loss and shorten survival in syngenic mice.Br J Cancer 67:939–944, 1993.

    PubMed  CAS  Google Scholar 

  13. Yasumoto K, Mukaida N, Harada A,et al: Molecular analysis of the cytokine network involved in cachexia in colon 26 adenocarcinoma-bearing mice.Cancer Res 55:921–927, 1995.

    PubMed  CAS  Google Scholar 

  14. Tsujinaka T, Fujita J, Ebisui C,et al: Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice.J Clin Invest 97:244–249, 1996.

    Article  PubMed  CAS  Google Scholar 

  15. Billingsley KG, Fraker DL, Strassmann G,et al: Macrophage-derived tumor necrosis factor and tumor-derived of leukemia inhibitory factor and interleukin-6: possible cellular mechanisms of cancer cachexia.Ann Surg Oncol 3:29–35, 1996.

    Article  PubMed  CAS  Google Scholar 

  16. Kajimura N, Iseki H, Tanaka R,et al: Toxohormones responsible for cancer cachexia syndrome in nude mice bearing human cancer cell lines.Cancer Chemother Pharmacol 38:48–52, 1996.

    Article  Google Scholar 

  17. Oka M, Yamamoto K, Takahashi M,et al: Relationship between serum levels of interleukin 6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma.Cancer Res 56:2776–2780, 1996.

    PubMed  CAS  Google Scholar 

  18. Yokoe T, lino Y, Takei H,et al: Changes of cytokines and thyroid function in patients with recurrent breast cancer.Anticancer Res 17:695–699, 1997.

    PubMed  CAS  Google Scholar 

  19. Zhang GJ, Adachi I: Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma.Anticancer Res 19:1427–1432, 1999.

    PubMed  CAS  Google Scholar 

  20. Yamashita J, Hideshima T, Shirakusa T,et al: Medroxyprogesterone acetate treatment reduces serum interleukin-6 levels in patients with metastatic breast carcinoma.Cancer 78:2346–2352, 1996.

    Article  PubMed  CAS  Google Scholar 

  21. Kurebayashi J, Otsuki T, Tang CK,et al: Isolation and characterisation of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and Interleukin-6.Br J Cancer 79:707–717, 1999.

    Article  PubMed  CAS  Google Scholar 

  22. Kurebayashi J, Yamamoto S, Otsuki T,et al: Medroxyprogesterone acetate inhibits interleukin-6 secretion from KPL-4 human breast cancer cell line both in vitro and in vivo: a possible mechanism of the anticachectic effect.Br J Cancer 79:631–636, 1999.

    Article  PubMed  CAS  Google Scholar 

  23. Yamamoto S, Kurebayashi J, Kunisue H,et al: Doxifluridine decreases serum levels of interleukin-6 in a cancer cachexia model.Gan To Kagaku Ryoho 26:1443–1448, 1999.

    PubMed  CAS  Google Scholar 

  24. Yamamoto S, Kurebayashi J, Kurosumi S,et al: Combined effects of docetaxel and fluoropyrimidines on tumor growth and expression of interleukin-6 and thymidine phosphorylase in breast cancer xenografts, (in submission)

  25. Fontanini G, Campani D, Roncella M,et al: Expression of interleukin 6 (IL-6) correlates with oestrogen receptor in human breast carcinoma.Br J Cancer 80:579–584, 1999.

    Article  PubMed  CAS  Google Scholar 

  26. Kawano M, Hirano T, Matsuda T,et al: Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas.Nature 332:83–85, 1988.

    Article  PubMed  CAS  Google Scholar 

  27. Miki S, Iwano M, Miki Y,et al: Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas.FEBS Lett 250:607–610, 1989.

    Article  PubMed  CAS  Google Scholar 

  28. Okamoto M, Lee C, Oyasu R: Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cell.in vitro. Cancer Res 57:141–146, 1997.

    CAS  Google Scholar 

  29. Guise TA, Yin JJ, Taylor SD,et al: Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest :1544–1549, 1996.

  30. Beutler B, Cerani A: Cachectin and tumor necrosis factor as two sides of the same biological coin.Nature 320:584–588, 1986.

    Article  PubMed  CAS  Google Scholar 

  31. Moldawer LL, Andersson C, Glein J,et al: Regulation of food intake and hepatic protein synthesis by recombinant-derived cytokines.Am J Physiol 254:450–456, 1988.

    Google Scholar 

  32. Ohsumi J, Miyadai K, Kawashima I,et al: Regulation of lipoprotein lipase synthesis in 3T3-L1 adipocytes by interleukin-11/adipogenesis inhibitory factor.Biochem Mol Biol Int 32:705–712, 1994.

    PubMed  CAS  Google Scholar 

  33. Matthys P, Dijkmans R, Proost P,et al: Severe cachexia in mice inoculated with interferon-γ-producing tumor cells.Int J Cancer 49:77–82, 1991.

    Article  PubMed  CAS  Google Scholar 

  34. Metcalf D, Nicola NA, Gearing DP: Effects of leukemia inhibitory factor on hematopoietic and other tissues in mice.Blood 76:50–56, 1990.

    PubMed  CAS  Google Scholar 

  35. Todorov P, Cariuk P, McDevitt T,et al: Characterization of a cancer cachectic factor.Nature 379:739–742, 1996.

    Article  PubMed  CAS  Google Scholar 

  36. Maltoni M, Fabbri L, Nanni O,et al: Serum levels of tumour necrosis factor alpha and other cytokines do not correlate with weight loss and anorexia in cancer patients.Support Care Cancer 5:130–135, 1997.

    Article  PubMed  CAS  Google Scholar 

  37. Mori K, Fujimoto-Ouchi K, Ishikawa T,et al: Murine interleukin-12 prevents the development of cancer cachexia in a murine model.Int J Cancer 67:849–855, 1996.

    Article  PubMed  CAS  Google Scholar 

  38. Mantovani G, Maccio A, Esu S,et al: Medroxyprogesterone acetate reduces th.in vitro production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients.Eur J Cancer 33:602–607, 1997.

    Article  PubMed  CAS  Google Scholar 

  39. Poulin R, Baker D, Poirier D,et al: Androgen and glucocorticoid receptor-mediated inhibition of cell proliferation by medroxyprogesterone acetate in ZR- 75-1 human breast cancer cells.Breast Cancer Res Treat 13:161–172, 1989.

    Article  PubMed  CAS  Google Scholar 

  40. Ray A, LaForge KS, Sehgal PB: On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids; Enhancer, TATA box, and RNA start site (Inr motif) occlusion.Mol Cell Biol 10:5736–5746, 1990.

    PubMed  CAS  Google Scholar 

  41. Tominaga T, Abe O, Ohshima A,et al: Comparison of chemotherapy with or without medroxyprogesterone acetate for advanced or recurrent breast cancer.Eur J Cancer 30:959–964, 1994.

    Article  Google Scholar 

  42. Downer S, Joel S, Allbright A,et al: A double blind placebo controlled trial of medroxyprogesterone acetate (MPA) in cancer cachexia.Br J Cancer 67:1102–1105, 1993.

    PubMed  CAS  Google Scholar 

  43. Kurebayashi J, Kurosumi M, Sonoo H: A new human breast cancer cell line, KPL-3C, secretes parathyroid hormone-related protein and produces tumours associated with microcalcifications in nude mice.Br J Cancer 74:200–207, 1996.

    PubMed  CAS  Google Scholar 

  44. Sawada N, Ishikawa T, Fukase Y,et al: Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin.Cancer Res 4:1013–1019, 1998.

    CAS  Google Scholar 

  45. Sumizawa T, Furukawa T, Haraguchi M,et al: Thymidine phosphorylase activity associated with plateletderived endothelial cell growth factor.J Biochem 114:9–14, 1993.

    PubMed  CAS  Google Scholar 

  46. Matsui H, Ihara Y, Fujio Y,et al: Induction of interleukin (IL)-6 by hypoxia is mediated by nuclear factor (NF)-kappa B and NF-IL6 in cardiac myocytes.Cardiovasc Res 1999 42:104–112, 1999.

    Article  CAS  Google Scholar 

  47. Schwartz EL, Wan E, Wang FS,et al: Regulation of expression of thymidine phosphorylase/plateletderived endothelial cell growth factor in human colon carcinoma cells.Cancer Res 58:1551–1557, 1998.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Breast and Thyroid Surgery, Kawasaki Medical School, Japan

    Junichi Kurebayashi

Authors
  1. Junichi Kurebayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

About this article

Cite this article

Kurebayashi, J. Regulation of interleukin-6 secretion from breast cancer cells and its clinical implications. Breast Cancer 7, 124–129 (2000). https://doi.org/10.1007/BF02967443

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02967443

Key words

Search

Navigation